P&P Law Firm advises pharmaceutical companies, manufacturers and distributors of medical devices, private healthcare providers, supply-chain operators and investors entering the healthcare sector. The firm has offices in Rome and Milan, more than twenty years of experience and a network of over 200 lawyers across Italy. What we offer is a coordinated approach to the corporate, contractual, regulatory and tax issues that, in this industry, are almost always intertwined.
How we assist our clients
We support clients at every stage of their business, from setting up a company to extraordinary transactions. In particular, we advise on:
- corporate transactions and M&A: acquisitions and disposals of companies and business units, due diligence, joint ventures, and the entry of new shareholders and investors;
- agreements with distributors, agents and commercial partners, including foreign operators;
- licensing, collaboration, co-marketing and development agreements, with particular attention to intellectual property and know-how;
- financing and financial structures supporting investments, acquisitions and working capital;
- contracts with public and private healthcare facilities, including supply arrangements and framework agreements;
- regulatory matters: authorisations, dealings with the competent authorities and alignment of contractual documentation with sector rules;
- tax planning and assistance in tax audits, coordinated with the corporate aspects of each transaction.
Typical transactions and situations
The requests we receive in this sector vary widely. By way of general illustration only, typical scenarios include the following:
- typically, an investment fund or industrial group considers acquiring a company active in the distribution of healthcare products and needs legal and tax due diligence;
- for example, an Italian pharmaceutical company wishes to entrust the marketing of one of its products to a foreign distributor and must settle exclusivity, territory, quality obligations and liability;
- the owner of a healthcare technology may wish to license it to an industrial partner and regulate ownership of results, royalties and the sharing of development costs;
- a private healthcare provider may need to renegotiate supply contracts or reorganise its corporate structure ahead of the entry of new shareholders.
Legal and tax aspects to consider
The sector is heavily regulated, and every transaction must be assessed in light of the applicable rules. Some recurring points:
- Legislative Decree 219/2006, implementing the Community code on medicinal products for human use, governs, among other things, authorisation, manufacturing and distribution of medicines; AIFA, the Italian Medicines Agency, plays a central role in the related procedures;
- Legislative Decree 502/1992 on the reorganisation of healthcare regulation, together with the rules on accreditation of healthcare facilities, affects relationships with the national health service and the structure of providers;
- health data is a special category of personal data: the GDPR requires a valid legal basis, security measures and enhanced safeguards, which should be reflected in contracts and operational processes;
- in extraordinary transactions, it is advisable to check carefully whether authorisations, accreditations and contracts with public bodies can be transferred;
- from a tax standpoint, the characterisation of payment flows (royalties, service fees, intra-group transfer pricing) calls for a case-by-case analysis.
Frequently asked questions
What legal issues should be checked before acquiring a healthcare company?
Beyond the usual corporate, tax and employment due diligence, it is necessary to review licences and authorisations, any accreditations, contracts with public bodies and key suppliers, compliance with health data rules and pending disputes. The outcome of these checks affects price, contractual warranties and the structure of the deal.
Does a distribution agreement for medicines or medical devices require special clauses?
Usually it does. In addition to the typical terms (territory, exclusivity, duration, pricing), it is advisable to address quality obligations, traceability, handling of adverse event reports and market withdrawals, compliance with applicable rules and the consequences of breach. The specific content depends on the product type and the markets involved.
How is intellectual property protected in a licence agreement?
It is important to define precisely the scope of the licence, ownership of any improvements and of the results of joint development, duration, territories, confidentiality and royalties. Careful drafting reduces the risk of disputes and makes later transactions involving the company or the technology easier to carry out.
What privacy obligations apply to health data?
Health data is a special category of personal data, and the GDPR sets stricter requirements for its processing: an appropriate legal basis, privacy notices, security measures and, in many cases, impact assessments. The roles and responsibilities of the parties should also be set out in contracts with suppliers and partners.
Can a private healthcare provider change its ownership structure without affecting its accreditation?
It depends on regional legislation and on the accreditation measures, which may require notifications or authorisations in the event of changes in ownership or control. Before proceeding, it is advisable to verify the applicable requirements and, where necessary, consult the competent authority, so as to avoid any impact on business continuity.
Let us talk
If you are assessing a transaction or need to review a contract in the pharmaceutical and healthcare sector, you can contact the firm for an initial discussion. You can learn more on our dedicated sector page or browse all the sectors we serve.
This content is for general information only and does not constitute legal or tax advice. For an assessment of your specific case, please consult a professional.
